HealthStream Announces Fourth Quarter & Full-Year 2022 Results, Initiation of Quarterly Cash Dividend, and Operational & Leadership Updates
Fourth Quarter 2022
-
Revenues of
$68.5 million , up 7% from$64.3 million in the fourth quarter of 2021 -
Operating income of
$3.1 million , up from an operating loss of$0.5 million in the fourth quarter of 20211 -
Net income of
$2.5 million , up from a net loss of$0.4 million in the fourth quarter of 20211 -
Earnings per share (EPS) of
$0.08 per share (diluted), compared to a loss of$0.01 per share (diluted) in the fourth quarter of 20211 -
Adjusted EBITDA2 of
$13.6 million , up 13% from$12.0 million in the fourth quarter of 2021 -
Completed the acquisition of
Electronic Education Documentation System, LLC (d/b/a “eeds”), aNorth Carolina -based healthcare technology company, onDecember 31, 2022
Full-Year 2022
-
Revenues of
$266.8 million , up 4% from$256.7 million in 2021 -
Operating income of
$12.4 million , up 55% from$8.1 million in 20211 -
Net income of
$12.1 million , up 107% from$5.8 million in 20211 -
Earnings per share (EPS) of
$0.39 per share (diluted) in 2022, compared to$0.18 per share (diluted) in 20211 -
Adjusted EBITDA of
$53.4 million , up 1% from$52.7 million in 2021
2023 Updates
- Operational and management updates made, affirming single platform strategy
-
Board of Directors adopts a quarterly cash dividend policy, with an initial quarterly dividend of
$0.025 per share, with the initial dividend being payable onApril 28, 2023 to holders of record onApril 17, 2023 , and expected aggregate fiscal 2023 dividends of approximately$3.0 million
1 Operating income, net income, and EPS for the three and twelve months ended |
2 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release. |
Financial Results:
Fourth Quarter 2022 Compared to Fourth Quarter 2021
Revenues for the fourth quarter of 2022 increased by
Revenues from our Workforce Solutions segment were
Revenues from our Provider Solutions segment were
Prior to the Company adopting ASU 2021-08 on
Operating income was
Net income was
Adjusted EBITDA was
At
Full-Year 2022 Compared to Full-Year 2021
For 2022, revenues were
Other Business Updates
As of
On
On
Adoption of Dividend Policy
The Company’s Board of Directors (“Board”) has approved a dividend policy under which we intend to pay a quarterly cash dividend on our common stock, at an initial rate of
Management Team Announcement
2023 Operational and Leadership Updates
HealthStream’s single platform strategy, as represented by our hStream technology platform, is transforming the way our Company is organized and managed. The Company’s operations and executive leadership are now shaped by the organizing principle of a single platform. Through this principle, operational efficiencies are realized, branding is simplified, and management structure is delayered. For example,
Organizing HealthStream’s business under a single platform strategy is resulting in several operational efficiencies across the Company, which include a reduction of 33 job roles, many of which are duplicative as a result of several areas of consolidation. Other operational efficiencies are being recognized through new departmental-level consolidations, a matrix management model across all solutions, and a reduction of several infrastructure expenses.
To provide executive-level leadership of HealthStream’s enterprise-level, single platform approach, updates in the Company’s management team have been made as well.
Beginning in
Financial Outlook for 2023
The Company is providing guidance for 2023 on a consolidated basis for the measures set forth below, including adjusted EBITDA, a non-GAAP financial measure as defined later in this release. For a reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) for 2023, see the table included on page 12 of this release.
|
|
Full-Year 2023 Guidance |
|||||
|
|
Low |
|
High |
|
||
Revenue |
|
$ |
277.5 |
- |
$ |
283.0 |
million |
|
|
|
|
|
|
|
|
Adjusted EBITDA1 |
|
$ |
57.5 |
- |
$ |
60.5 |
million |
|
|
|
|
|
|
|
|
Capital Expenditures |
|
$ |
27.0 |
- |
$ |
29.0 |
million |
1 Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release. |
The Company’s guidance for 2023 as set forth above reflects the Company’s assumptions regarding, among other things, the COVID-19 pandemic and current economic conditions as noted below. This consolidated guidance does not include the impact of any acquisitions that we may complete during 2023.
The Company’s financial guidance assumes that public health conditions associated with COVID-19 and current economic conditions, including in relation to ongoing inflationary and recessionary pressures, do not deteriorate during 2023, particularly with regard to how such conditions impact healthcare organizations.
Commenting on fourth quarter & full-year 2022 results,
A conference call with
Use of Non-GAAP Financial Measures
This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company’s financial results and ongoing operational performance. In order to better assess the Company’s financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses (as discussed in greater detail below) and before interest, income taxes, stock-based compensation, depreciation and amortization, changes in fair value of, including gains (losses) on the sale of, non-marketable equity investments, and the de-recognition of non-cash expense resulting from the PTO expense reduction in the first quarter of 2021 (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and/or non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operating performance and to compare the Company's operating performance between periods. In addition, short-term cash incentive bonuses and certain performance-based equity awards are based on the achievement of adjusted EBITDA (as defined in applicable bonus and equity grant documentation) targets.
As noted above, the definition of adjusted EBITDA includes an adjustment for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. Prior to the Company early adopting ASU 2021-08 effective
adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for businesses acquired prior to the
Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and has limitations as an analytical tool.
This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (the most comparable GAAP measure), which is set forth below in this release.
About
|
||||||||||||||||
Condensed Consolidated Statements of Income |
||||||||||||||||
(In thousands, except per share data) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Revenues, net |
|
$ |
68,536 |
|
|
$ |
64,338 |
|
|
$ |
266,826 |
|
|
$ |
256,712 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues (excluding depreciation and amortization) |
|
|
23,536 |
|
|
|
22,979 |
|
|
|
91,143 |
|
|
|
91,033 |
|
Product development |
|
|
11,807 |
|
|
|
11,454 |
|
|
|
44,277 |
|
|
|
41,659 |
|
Sales and marketing |
|
|
11,494 |
|
|
|
10,745 |
|
|
|
44,146 |
|
|
|
39,457 |
|
Other general and administrative expenses |
|
|
9,009 |
|
|
|
10,250 |
|
|
|
36,866 |
|
|
|
39,695 |
|
Depreciation and amortization |
|
|
9,611 |
|
|
|
9,370 |
|
|
|
37,945 |
|
|
|
36,813 |
|
Total operating costs and expenses |
|
|
65,457 |
|
|
|
64,798 |
|
|
|
254,377 |
|
|
|
248,657 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
3,079 |
|
|
|
(460 |
) |
|
|
12,449 |
|
|
|
8,055 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (loss), net |
|
|
191 |
|
|
|
(39 |
) |
|
|
3,136 |
|
|
|
(289 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax provision |
|
|
3,270 |
|
|
|
(499 |
) |
|
|
15,585 |
|
|
|
7,766 |
|
Income tax provision (benefit) |
|
|
819 |
|
|
|
(112 |
) |
|
|
3,494 |
|
|
|
1,921 |
|
Net income (loss) |
|
$ |
2,451 |
|
|
$ |
(387 |
) |
|
$ |
12,091 |
|
|
$ |
5,845 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.08 |
|
|
$ |
(0.01 |
) |
|
$ |
0.39 |
|
|
$ |
0.19 |
|
Diluted |
|
$ |
0.08 |
|
|
$ |
(0.01 |
) |
|
$ |
0.39 |
|
|
$ |
0.18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares of common stock outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
30,574 |
|
|
|
31,520 |
|
|
|
30,648 |
|
|
|
31,534 |
|
Diluted |
|
|
30,717 |
|
|
|
31,520 |
|
|
|
30,717 |
|
|
|
31,618 |
|
|
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
|
|
|
|
|
||
|
|
2022 |
|
|
2021 |
|
||
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
46,023 |
|
|
$ |
46,905 |
|
Marketable securities |
|
|
7,885 |
|
|
|
5,041 |
|
Accounts and unbilled receivables, net |
|
|
42,710 |
|
|
|
34,920 |
|
Prepaid and other current assets |
|
|
17,759 |
|
|
|
19,979 |
|
Total current assets |
|
|
114,377 |
|
|
|
106,845 |
|
|
|
|
|
|
|
|
|
|
Capitalized software development, net |
|
|
37,118 |
|
|
|
32,412 |
|
Property and equipment, net |
|
|
15,483 |
|
|
|
17,950 |
|
Operating lease right of use assets, net |
|
|
22,759 |
|
|
|
25,168 |
|
|
|
|
273,951 |
|
|
|
271,706 |
|
Deferred tax assets |
|
|
383 |
|
|
|
601 |
|
Deferred commissions, net |
|
|
28,344 |
|
|
|
24,012 |
|
Other assets |
|
|
5,326 |
|
|
|
8,059 |
|
Total assets |
|
$ |
497,741 |
|
|
$ |
486,753 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable, accrued and other liabilities |
|
$ |
37,744 |
|
|
$ |
26,534 |
|
Deferred revenue |
|
|
79,469 |
|
|
|
73,816 |
|
Total current liabilities |
|
|
117,213 |
|
|
|
100,350 |
|
Deferred tax liabilities |
|
|
17,996 |
|
|
|
18,146 |
|
Deferred revenue, non-current |
|
|
2,937 |
|
|
|
1,583 |
|
Operating lease liability, non-current |
|
|
23,321 |
|
|
|
26,178 |
|
Other long-term liabilities |
|
|
2,210 |
|
|
|
1,477 |
|
Total liabilities |
|
|
163,677 |
|
|
|
147,734 |
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity: |
|
|
|
|
|
|
|
|
Common stock |
|
|
254,832 |
|
|
|
270,791 |
|
Accumulated other comprehensive (loss) income |
|
|
(981 |
) |
|
|
106 |
|
Retained earnings |
|
|
80,213 |
|
|
|
68,122 |
|
Total shareholders’ equity |
|
|
334,064 |
|
|
|
339,019 |
|
Total liabilities and shareholders' equity |
|
$ |
497,741 |
|
|
$ |
486,753 |
|
|
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
Year Ended |
|
|||||
|
|
|
|
|
|
|
||
|
|
2022 |
|
|
2021 |
|
||
Operating activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
12,091 |
|
|
$ |
5,845 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
37,945 |
|
|
|
36,813 |
|
Amortization of deferred commissions |
|
|
10,599 |
|
|
|
9,169 |
|
Stock-based compensation |
|
|
3,554 |
|
|
|
5,303 |
|
Deferred income taxes |
|
|
710 |
|
|
|
1,539 |
|
Provision for credit losses |
|
|
385 |
|
|
|
723 |
|
(Gain) Loss on disposal of fixed assets |
|
|
(25 |
) |
|
|
21 |
|
Loss on equity method investments |
|
|
747 |
|
|
|
462 |
|
Non-cash paid time off expense |
|
|
— |
|
|
|
(1,011 |
) |
Change in fair value of non-marketable equity investments |
|
|
(3,596 |
) |
|
|
(279 |
) |
Other |
|
|
3 |
|
|
|
184 |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts and unbilled receivables |
|
|
(7,770 |
) |
|
|
10,344 |
|
Deferred commissions |
|
|
(14,931 |
) |
|
|
(13,274 |
) |
Prepaid and other assets |
|
|
2,621 |
|
|
|
2,240 |
|
Accounts payable, accrued and other liabilities |
|
|
4,148 |
|
|
|
(8,101 |
) |
Deferred revenue |
|
|
4,707 |
|
|
|
(7,593 |
) |
Net cash provided by operating activities |
|
|
51,188 |
|
|
|
42,385 |
|
|
|
|
|
|
|
|
|
|
Investing activities: |
|
|
|
|
|
|
|
|
Business combinations, net of cash acquired |
|
|
(3,965 |
) |
|
|
(4,705 |
) |
Changes in marketable securities |
|
|
(2,842 |
) |
|
|
4,708 |
|
Proceeds from sale of non-marketable equity investments |
|
|
3,494 |
|
|
|
1,370 |
|
Payments to acquire non-marketable equity investments |
|
|
— |
|
|
|
(1,750 |
) |
Proceeds from sale of fixed assets |
|
|
26 |
|
|
|
— |
|
Purchases of property and equipment |
|
|
(1,768 |
) |
|
|
(3,417 |
) |
Payments associated with capitalized software development |
|
|
(23,334 |
) |
|
|
(21,929 |
) |
Net cash used in investing activities |
|
|
(28,389 |
) |
|
|
(25,723 |
) |
|
|
|
|
|
|
|
|
|
Financing activities: |
|
|
|
|
|
|
|
|
Taxes paid related to net settlement of equity awards |
|
|
(565 |
) |
|
|
(1,182 |
) |
Repurchases of common stock |
|
|
(23,137 |
) |
|
|
(5,008 |
) |
Payment of cash dividends |
|
|
— |
|
|
|
(19 |
) |
Net cash used in financing activities |
|
|
(23,702 |
) |
|
|
(6,209 |
) |
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
|
|
21 |
|
|
|
(114 |
) |
Net (decrease) increase in cash and cash equivalents |
|
|
(882 |
) |
|
|
10,339 |
|
Cash and cash equivalents at beginning of period |
|
|
46,905 |
|
|
|
36,566 |
|
Cash and cash equivalents at end of period |
|
$ |
46,023 |
|
|
$ |
46,905 |
|
Reconciliation of GAAP to Non-GAAP Financial Measures(1) |
||||||||||||||||
Operating Results Summary |
||||||||||||||||
(In thousands) |
||||||||||||||||
(Unaudited) |
||||||||||||||||
|
|
Three Months Ended |
|
|
Year Ended |
|
||||||||||
|
|
|||||||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
GAAP net income (loss) |
|
$ |
2,451 |
|
|
$ |
(387 |
) |
|
$ |
12,091 |
|
|
$ |
5,845 |
|
Deferred revenue write-down |
|
|
44 |
|
|
|
383 |
|
|
|
267 |
|
|
|
4,040 |
|
Interest income |
|
|
(289 |
) |
|
|
(15 |
) |
|
|
(444 |
) |
|
|
(80 |
) |
Interest expense |
|
|
33 |
|
|
|
33 |
|
|
|
132 |
|
|
|
132 |
|
Income tax provision (benefit) |
|
|
819 |
|
|
|
(112 |
) |
|
|
3,494 |
|
|
|
1,921 |
|
Stock-based compensation expense |
|
|
946 |
|
|
|
3,043 |
|
|
|
3,554 |
|
|
|
5,303 |
|
Depreciation and amortization |
|
|
9,611 |
|
|
|
9,370 |
|
|
|
37,945 |
|
|
|
36,813 |
|
Non-cash paid time off expense |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,011 |
) |
Change in fair value of non-marketable equity investments |
|
|
— |
|
|
|
(279 |
) |
|
|
(3,596 |
) |
|
|
(279 |
) |
Adjusted EBITDA |
|
$ |
13,615 |
|
|
$ |
12,036 |
|
|
$ |
53,443 |
|
|
$ |
52,684 |
|
(1) This press release presents adjusted EBITDA, which is a non-GAAP financial measure used by management in analyzing its financial results and ongoing operational performance. |
Reconciliation of GAAP to Non-GAAP Financial Measures |
||||||||
Financial Outlook for 2023 |
||||||||
(In thousands) |
||||||||
(Unaudited) |
||||||||
|
|
Low |
|
|
High |
|
||
Net income |
|
$ |
9,800 |
|
|
$ |
11,500 |
|
Deferred revenue write-down |
|
|
100 |
|
|
|
100 |
|
Interest income |
|
|
(1,000) |
|
|
|
(1,300) |
|
Interest expense |
|
|
100 |
|
|
|
100 |
|
Income tax provision |
|
|
3,400 |
|
|
|
4,000 |
|
Stock-based compensation expense |
|
|
3,900 |
|
|
|
4,500 |
|
Depreciation and amortization |
|
|
41,200 |
|
|
|
41,600 |
|
Adjusted EBITDA |
|
$ |
57,500 |
|
|
$ |
60,500 |
|
This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2023 as well as the anticipated impact of COVID-19 and current economic conditions, such as inflationary and recessionary pressures, on our financial results, and expectations regarding our quarterly dividend policy, that involve risks and uncertainties regarding
View source version on businesswire.com: https://www.businesswire.com/news/home/20230220005251/en/
Chief Financial Officer
(615) 301-3182
ir@healthstream.com
Media:
Vice President, Investor Relations
(615) 301-3237
mollie.condra@healthstream.com
Source: